The Application of EU Competition Law in the Pharmaceutical Sector by David W. Hull (Covington)
ABSTRACT: If the Court of Justice follows the Advocate General’s advice and upholds the General Court’s judgment in AstraZeneca, this may result in increased enforcement aimed at various life cycle management strategies. The Commission’s current enforcement priority remains combatting practices that slow generic entry, particularly reverse-payment patent settlements. The Commission has shown a renewed interest in parallel trade, particularly dual-pricing arrangements in Spain.
Featured News
Senator Warner Calls for Treasury Oversight on Big Tech Sanctions
Jan 29, 2024 by
CPI
Canada’s Industry Minister Targets Grocery Giants with Antitrust Changes
Jan 29, 2024 by
CPI
DOT Issues Provisional Ruling Ending Delta-Aeroméxico Partnership
Jan 29, 2024 by
CPI
US Targets China with Proposed Rules on Cloud Giants in AI Development
Jan 29, 2024 by
CPI
Australia’s ACCC Finds Limited Evidence of Profiteering in Childcare Sector Despite Soaring Fees
Jan 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Rule(s) of Reason
Jan 29, 2024 by
CPI
Evolving the Rule of Reason for Legacy Business Conduct
Jan 29, 2024 by
CPI
The Object Identity
Jan 29, 2024 by
CPI
In Praise of Rules-Based Antitrust
Jan 29, 2024 by
CPI
The Future of State AG Antitrust Enforcement and Federal-State Cooperation
Jan 29, 2024 by
CPI